Yury Bochkov, PhD

Position title: Senior Scientist III

Email: yabochkov@wisc.edu

Address:
Division of Allergy, Immunology, and Rheumatology

Yury Bochkov, PhD

Education

BS, Ivanovo State University, Ivanovo, Russia
MS, Ivanovo State University, Ivanovo, Russia
PhD, All-Russian Research Institute for Animal Health, Vladimir, Russia
Postdoctoral Fellowship, University of Wisconsin, Madison, Wisconsin

Professional Activities

Dr. Yury Bochkov is senior scientist III in the Division of Allergy, Immunology, and Rheumatology. Bochkov is a virologist with over 25 years of experience in molecular virology, immunology and diagnostics of several species of RNA viruses. Since 2004, he has been a full member of the American Society for Virology (ASV). He has presented his research findings at many national and international conferences, and has served as an ad hoc reviewer for the NIH Lung Cellular, Molecular, and Immunobiology (LCMI) study section and multiple peer-reviewed scientific journals in the field of virology, immunology and airway cell biology. He has also led the Virology / Microbiology Cores of two large NIH-funded grants. Additionally, he has served as principal investigator or co-investigator on several NIH-funded R01 and U19 grants as well as on industry-sponsored projects.

Research Interests

Bochkov’s current research interests are focused on studying molecular biology and immunology of human rhinovirus species C (RV-C), a respiratory pathogen associated with childhood wheezing. His work includes identification of host and viral determinants of neutralizing antibody responses, antigenic relationship between RV-C types and mapping major neutralizing epitopes. The goal of these studies is to enable formulation of a broadly protective, experimental polyvalent RV-C vaccine for prophylaxis of RV-C infection in vulnerable populations such as young children with asthma-risk genotype in viral receptor CDHR3. Some of  Bochkov ‘s ongoing collaborations include development of a mouse model of RV-C infection and mouse-adapted RV-C strains for evaluating efficacy of the RV-C vaccine, production of RV-C reference mouse sera, development of human monoclonal antibodies to RV, and study of the role of mitophagy in RV replication and release from airway epithelial cells.